Kodiak Sciences (KOD) | Financial Analysis & Statements
Kodiak Sciences Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-57.5M
Net Income
-56.7M
Balance Sheet Metrics
Total Assets
351.5M
Total Liabilities
194.2M
Shareholders Equity
157.4M
Debt to Equity
1.23
Cash Flow Metrics
Operating Cash Flow
-38.3M
Free Cash Flow
-39.4M
Revenue & Profitability Trend
Kodiak Sciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 182.4M | 126.1M | 206.3M | 267.6M | 217.3M |
| Selling, General & Administrative | 52.0M | 60.8M | 71.0M | 73.8M | 49.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 234.4M | 186.8M | 277.3M | 341.4M | 267.1M |
| Operating Income | -234.4M | -186.8M | -277.3M | -341.4M | -267.1M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 4.5M | 11.1M | 16.7M | 7.1M | 298.0K |
| Interest Expense | 0 | 0 | 13.0K | 18.0K | 47.0K |
| Other Non-Operating Income | -96.0K | -506.0K | 110.0K | 503.0K | -190.0K |
| Pre-tax Income | -230.0M | -176.2M | -260.5M | -333.8M | -267.0M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -230.0M | -176.2M | -260.5M | -333.8M | -267.0M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -203.6M | -149.5M | -234.5M | -322.8M | -258.2M |
| EPS (Basic) | $-4.32 | $-3.35 | $-4.97 | $-6.39 | $-5.16 |
| EPS (Diluted) | $-4.32 | $-3.35 | $-4.97 | $-6.39 | $-5.16 |
| Basic Shares Outstanding | 53208311 | 52583148 | 52414256 | 52249620 | 51788918 |
| Diluted Shares Outstanding | 53208311 | 52583148 | 52414256 | 52249620 | 51788918 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Kodiak Sciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 209.9M | 168.1M | 285.5M | 190.4M | 731.5M |
| Short-term Investments | - | - | 0 | 288.5M | 0 |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 5.0M | 3.9M | 3.8M | 7.1M | 3.3M |
| Total Current Assets | 214.8M | 171.9M | 289.3M | 486.0M | 734.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 36.6M | 46.5M | 54.5M | 59.4M | 66.7M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 14.9M | 14.9M | 15.0M | 64.9M | 61.3M |
| Total Non-Current Assets | 136.7M | 163.6M | 190.1M | 180.6M | 169.4M |
| Total Assets | 351.5M | 335.6M | 479.4M | 666.6M | 904.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 12.9M | 3.9M | 13.6M | 9.1M | 12.4M |
| Short-term Debt | 12.1M | 10.6M | 9.8M | 9.9M | 3.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | -1.0K | - |
| Total Current Liabilities | 45.5M | 25.6M | 41.7M | 52.5M | 64.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 47.1M | 59.7M | 71.9M | 77.8M | 76.1M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 101.5M | 100.0M | 100.0M | 100.2M | 211.0K |
| Total Non-Current Liabilities | 148.6M | 159.7M | 171.9M | 178.0M | 176.2M |
| Total Liabilities | 194.2M | 185.3M | 213.6M | 230.5M | 240.9M |
| Equity | |||||
| Common Stock | 6.0K | 5.0K | 5.0K | 5.0K | 5.0K |
| Retained Earnings | -1.6B | -1.3B | -1.2B | -892.0M | -558.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 157.4M | 150.3M | 265.8M | 436.2M | 663.3M |
| Key Metrics | |||||
| Total Debt | 59.2M | 70.3M | 81.6M | 87.7M | 80.0M |
| Working Capital | 169.3M | 146.4M | 247.6M | 433.5M | 670.1M |
Balance Sheet Composition
Kodiak Sciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -230.0M | -176.2M | -260.5M | -333.8M | -267.0M |
| Depreciation & Amortization | 26.3M | 26.7M | 25.9M | 11.0M | 8.7M |
| Stock-Based Compensation | 58.9M | 60.2M | 88.6M | 106.0M | 61.4M |
| Working Capital Changes | -3.0M | -21.0M | -2.9M | 17.0M | 1.2M |
| Operating Cash Flow | -147.8M | -109.9M | -148.9M | -200.4M | -195.7M |
| Investing Activities | |||||
| Capital Expenditures | -506.0K | -400.0K | -41.4M | -47.4M | -63.3M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | 0 | -355.0K | -49.3M | -427.8M | 0 |
| Investment Sales | 0 | 0 | 340.0M | 138.6M | 24.5M |
| Investing Cash Flow | -506.0K | -755.0K | 249.2M | -336.5M | -38.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | 0 | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | 0 | 0 |
| Financing Cash Flow | 173.0M | - | -211.0K | -49.0K | -45.0K |
| Free Cash Flow | -136.5M | -117.7M | -195.6M | -253.8M | -245.6M |
| Net Change in Cash | 24.7M | -110.6M | 100.1M | -537.0M | -234.5M |
Cash Flow Trend
Kodiak Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-10.48
Forward P/E
-13.23
Price to Book
17.70
PEG Ratio
-0.44
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-149.49%
Return on Assets
-42.64%
Financial Health
Current Ratio
4.72
Debt to Equity
37.60
Beta
2.40
Per Share Data
EPS (TTM)
$-4.32
Book Value per Share
$2.55
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| KOD | 2.8B | -10.48 | 17.70 | -149.49% | 0.00% | 37.60 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






